Nucleic Acid Aptamers as Stabilizers of Proteins: The Stability of Tetanus Toxoid

PurposeExposure of tetanus toxoid to moisture leads to its aggregation and reduction of potency. The aim of this work was to use SELEX (systematic evolution of ligands by exponential enrichment) protocol and select aptamers which recognize tetanus toxoid (Mr ~150 kDa) with high affinity.MethodsColyophilized preparations of tetanus toxoid and specific aptamers were encapsulated in PLGA microspheres and sustained release of the antigen was observed up to 55 days using different techniques.ResultsThe total protein released was between 40–55% (24–45% residual antigenicity) in the presence of the aptamers as compared to 25% (11% residual antigenicity) for the antigen alone. We show that instead of inhibiting absorption of moisture, the aptamers blocked the protein unfolding upon absorption of moisture, inhibiting the initiation of aggregation. When exposed to accelerated storage conditions, some of the RNA sequences were able to inhibit moisture-induced aggregation in vitro and retain antigenicity of tetanus toxoid.ConclusionsNucleic acid aptamers represent a novel class of protein stabilizers which stabilize the protein by interacting directly with it. This mechanism is unlike that of small molecules which alter the medium properties and hence depend on the stress condition a protein is exposed to.

[1]  N. Jain,et al.  Accelerated Stability Studies for Moisture-Induced Aggregation of Tetanus Toxoid , 2011, Pharmaceutical Research.

[2]  Debra Kristensen,et al.  Stabilization of vaccines: Lessons learned , 2010, Human vaccines.

[3]  R. Gupta,et al.  Stabilization of tetanus and diphtheria toxoids against moisture-induced aggregation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[4]  D. Draper,et al.  The linkage between magnesium binding and RNA folding. , 2002, Journal of molecular biology.

[5]  H. Aggerbeck,et al.  Detoxification of diphtheria and tetanus toxin with formaldehyde. Detection of protein conjugates. , 1992, Biologicals : journal of the International Association of Biological Standardization.

[6]  G. Hermanson,et al.  Immobilized Affinity Ligand Techniques , 1992 .

[7]  L. Cerchia,et al.  Targeting cancer cells with nucleic acid aptamers. , 2010, Trends in biotechnology.

[8]  B. V. D. van der Zeijst.  Vaccines and global stability: achievements and challenges , 2008, Expert review of vaccines.

[9]  Xiaobing Zhang,et al.  Molecular aptamers for drug delivery. , 2011, Trends in biotechnology.

[10]  Robert C. Edgar,et al.  Multiple sequence alignment. , 2006, Current opinion in structural biology.

[11]  R. J. Solá,et al.  The relation between moisture‐induced aggregation and structural changes in lyophilized insulin , 2009, The Journal of pharmacy and pharmacology.

[12]  Koji Sode,et al.  Screening and Improvement of an Anti-VEGF DNA Aptamer , 2010, Molecules.

[13]  Yong Wang,et al.  Hydrogel functionalization with DNA aptamers for sustained PDGF-BB release. , 2010, Chemical communications.

[14]  P. K. Smith,et al.  Measurement of protein using bicinchoninic acid. , 1985, Analytical biochemistry.

[15]  J. Thompson,et al.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.

[16]  N. Jain,et al.  Stabilization of tetanus toxoid formulation containing aluminium hydroxide adjuvant against freeze-thawing. , 2011, International journal of pharmaceutics.

[17]  B. Seong,et al.  Chaperoning Roles of Macromolecules Interacting with Proteins in Vivo , 2011, International journal of molecular sciences.

[18]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[19]  A. Pardi,et al.  A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[20]  R. Landgraf,et al.  Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[21]  H. Schellekens.  Follow-on biologics: challenges of the "next generation". , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[22]  Thomas W. Patapoff,et al.  Opposite Effects of Polyols on Antibody Aggregation: Thermal Versus Mechanical Stresses , 2011, Pharmaceutical Research.

[23]  Kai Griebenow,et al.  Moisture-induced solid state instabilities in α-chymotrypsin and their reduction through chemical glycosylation , 2010, BMC biotechnology.

[24]  G. Kresse.  Biosimilars--science, status, and strategic perspective. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[25]  Wenlei Jiang,et al.  Stabilization of tetanus toxoid encapsulated in PLGA microspheres. , 2008, Molecular pharmaceutics.

[26]  B. Narasimhan,et al.  Protein stability in the presence of polymer degradation products: consequences for controlled release formulations. , 2006, Biomaterials.

[27]  B. Seong,et al.  RNA-mediated chaperone type for de novo protein folding , 2009, RNA biology.

[28]  T. Nagai,et al.  Pharmaceutical and immunological evaluation of a single-dose hepatitis B vaccine using PLGA microspheres. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[29]  Joan W. Miller,et al.  Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres. , 2003, Investigative ophthalmology & visual science.

[30]  D. Bunka,et al.  Development of aptamer therapeutics. , 2010, Current opinion in pharmacology.

[31]  Chung C. Hsu,et al.  Effect of Moisture on the Stability of a Lyophilized Humanized Monoclonal Antibody Formulation , 2001, Pharmaceutical Research.

[32]  D. Patel,et al.  Adaptive recognition by nucleic acid aptamers. , 2000, Science.

[33]  N. Jain,et al.  Stabilization of tetanus toxoid formulation containing aluminium hydroxide adjuvant against agitation. , 2012, International journal of pharmaceutics.

[34]  R. Karimov,et al.  A mid-term assessment of progress towards the immunization coverage goal of the Global Immunization Vision and Strategy (GIVS) , 2011, BMC public health.

[35]  Ioannis Xenarios,et al.  T-Coffee: a web server for the multiple sequence alignment of protein and RNA sequences using structural information and homology extension , 2011, Nucleic Acids Res..

[36]  Wenlei Jiang,et al.  Formaldehyde-mediated aggregation of protein antigens: comparison of untreated and formalinized model antigens. , 2000, Biotechnology and bioengineering.

[37]  V. Uversky,et al.  Evidence for a Partially Folded Intermediate in α-Synuclein Fibril Formation* , 2001, The Journal of Biological Chemistry.

[38]  U. Hahn,et al.  Aptamers to Small Molecules , 2006 .

[39]  Harald Schumny,et al.  Next generation , 2005, Comput. Stand. Interfaces.

[40]  Yong Wang,et al.  Affinity hydrogels for controlled protein release using nucleic acid aptamers and complementary oligonucleotides. , 2011, Biomaterials.

[41]  M. H. D. da Costa,et al.  Evaluation of a diphtheria and tetanus PLGA microencapsulated vaccine formulation without stabilizers. , 2009, Current drug delivery.

[42]  S. Tope,et al.  Aptamers as therapeutics , 2013 .

[43]  Anubhav Jain,et al.  Development of a single dose tetanus toxoid formulation based on polymeric microspheres: a comparative study of poly(D,L-lactic-co-glycolic acid) versus chitosan microspheres. , 2005, International journal of pharmaceutics.

[44]  B. V. D. Zeijst.  Vaccines and global stability: achievements and challenges , 2008 .

[45]  B. Seong,et al.  Protein Solubility and Folding Enhancement by Interaction with RNA , 2008, PloS one.

[46]  J. O’brien.  Advancing vaccinology in India , 2012, Expert review of vaccines.

[47]  Andrew R Fox.  Biosimilar Medicines—New Challenges for a New Class of Medicine , 2009, Journal of biopharmaceutical statistics.

[48]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[49]  A. Klibanov,et al.  The secondary structure and aggregation of lyophilized tetanus toxoid. , 1996, Journal of pharmaceutical sciences.